globus medical nevro - Search News

Nevro, Globus

Medical Device Network on MSN · 19h

Globus Medical strengthens SCS market position with $250m Nevro deal

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Yahoo Finance · 4d

Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,

Fierce Biotech · 22h

Globus Medical to buy neurostim developer Nevro for $250M

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. | With Globus paying $5.85 for each of Nevro’s outstanding shares,

Zacks.com on MSN4d

Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?

Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Nasdaq4d

Globus Medical to Acquire Nevro Corp. in All-Cash Transaction Valued at $250 Million

Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an ...

Globus Medical to acquire Nevro for $5.85 per share

Globus Medical (GMED) and Nevro Corp. (NVRO) have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an ...

Hosted on MSN4d

Nevro upgraded to Neutral from Underweight at Piper Sandler

Piper Sandler analyst Adam Maeder upgraded Nevro (NVRO) to Neutral from Underweight with a price target of $5.85, down from $6, after the company ...

TMCnet4d

Shareholder Alert: Ademi & Fruchter LLP Investigates Whether Nevro Corp. Is Obtaining a Fair Price for Its Public Shareholders

Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.

Nevro upgraded to Hold from Underperform at Jefferies

Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results